{"title":"人外周血CD19+CD5+CD1d+产生白细胞介素10和转化生长因子β1的调节性B细胞的表型鉴定","authors":"Md Rezaul Karim, Yun-fu Wang","doi":"10.5114/aoms.2018.77772","DOIUrl":null,"url":null,"abstract":"Introduction Regulatory B cells (Bregs), a novel subpopulation of B cells, are a significant area of research due to their immune regulatory function in the immunological response. Bregs have been reported to regulate acute inflammation and immunity through the production of anti-inflammatory cytokines. Material and methods A B cell subpopulation was identified using flow cytometric analysis in two different processes: 1) after preparation and storage of peripheral blood mononuclear cells (PBMCs) using Ficoll density gradient centrifugation from a human blood sample, 2) followed by isolation and storage of B cells through magnetic separation using a B cell isolation kit and MS column. ELISA assays were performed to observe the cytokine production of interkleukin 10 (IL-10) and transforming growth factor β1 (TGF-β1) by this novel B cell subpopulation. Results Double positive staining of CD5+CD1d+ Bregs represents (19.27 ±1.52) from PBMCs, (33.32 ±2.95) from B cells accordingly (n = 40). Through ELISA assays, it has been found that B cell subpopulation produces IL-10 (0.56 ±0.08) and TGF-β1 (0.90 ±0.12) (n = 40). Conclusions These methods should be able to facilitate progress in research on Bregs through the following steps: 1) the regulatory role may be observed in comparison with particular autoimmune diseases, inflammation, cancer, and immunologic responses to find out whether Breg alteration and/or cytokine production is altered as well in these disorders or conditions. 2) If the alteration of Bregs and cytokine production is significant along with the clinical correlation, a further in vitro study can be initiated with exposure of certain drugs to overcome the alteration of the cytokine production; then, an in vivo study can be initiated.","PeriodicalId":190584,"journal":{"name":"Archives of Medical Science : AMS","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":"{\"title\":\"Phenotypic identification of CD19+CD5+CD1d+ regulatory B cells that produce interleukin 10 and transforming growth factor β1 in human peripheral blood\",\"authors\":\"Md Rezaul Karim, Yun-fu Wang\",\"doi\":\"10.5114/aoms.2018.77772\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction Regulatory B cells (Bregs), a novel subpopulation of B cells, are a significant area of research due to their immune regulatory function in the immunological response. Bregs have been reported to regulate acute inflammation and immunity through the production of anti-inflammatory cytokines. Material and methods A B cell subpopulation was identified using flow cytometric analysis in two different processes: 1) after preparation and storage of peripheral blood mononuclear cells (PBMCs) using Ficoll density gradient centrifugation from a human blood sample, 2) followed by isolation and storage of B cells through magnetic separation using a B cell isolation kit and MS column. ELISA assays were performed to observe the cytokine production of interkleukin 10 (IL-10) and transforming growth factor β1 (TGF-β1) by this novel B cell subpopulation. Results Double positive staining of CD5+CD1d+ Bregs represents (19.27 ±1.52) from PBMCs, (33.32 ±2.95) from B cells accordingly (n = 40). Through ELISA assays, it has been found that B cell subpopulation produces IL-10 (0.56 ±0.08) and TGF-β1 (0.90 ±0.12) (n = 40). Conclusions These methods should be able to facilitate progress in research on Bregs through the following steps: 1) the regulatory role may be observed in comparison with particular autoimmune diseases, inflammation, cancer, and immunologic responses to find out whether Breg alteration and/or cytokine production is altered as well in these disorders or conditions. 2) If the alteration of Bregs and cytokine production is significant along with the clinical correlation, a further in vitro study can be initiated with exposure of certain drugs to overcome the alteration of the cytokine production; then, an in vivo study can be initiated.\",\"PeriodicalId\":190584,\"journal\":{\"name\":\"Archives of Medical Science : AMS\",\"volume\":\"6 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Science : AMS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/aoms.2018.77772\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Science : AMS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/aoms.2018.77772","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16
摘要
调节性B细胞(Regulatory B cells, Bregs)是一种新型的B细胞亚群,由于其在免疫应答中的免疫调节功能而成为一个重要的研究领域。据报道,Bregs通过产生抗炎细胞因子来调节急性炎症和免疫。材料和方法:采用两种不同的流程,流式细胞术对B细胞亚群进行鉴定:1)用Ficoll密度梯度离心法从人血液样品中制备和储存外周血单个核细胞(PBMCs), 2)用B细胞分离试剂盒和质谱柱通过磁分离分离和储存B细胞。ELISA法观察该新型B细胞亚群产生白细胞介素10 (IL-10)和转化生长因子β1 (TGF-β1)。结果PBMCs细胞CD5+CD1d+ Bregs双阳性染色为(19.27±1.52)个,B细胞为(33.32±2.95)个。ELISA检测发现B细胞亚群产生IL-10(0.56±0.08)和TGF-β1(0.90±0.12)(n = 40)。结论这些方法应该能够通过以下步骤促进Breg的研究进展:1)可以通过与特定自身免疫性疾病、炎症、癌症和免疫反应的比较来观察Breg的调节作用,以发现Breg的改变和/或细胞因子的产生是否也在这些疾病或条件下改变。2)如果Bregs和细胞因子产生的改变具有显著性,且具有临床相关性,则可以通过暴露某些药物来克服细胞因子产生的改变,进一步开展体外研究;然后,可以启动体内研究。
Phenotypic identification of CD19+CD5+CD1d+ regulatory B cells that produce interleukin 10 and transforming growth factor β1 in human peripheral blood
Introduction Regulatory B cells (Bregs), a novel subpopulation of B cells, are a significant area of research due to their immune regulatory function in the immunological response. Bregs have been reported to regulate acute inflammation and immunity through the production of anti-inflammatory cytokines. Material and methods A B cell subpopulation was identified using flow cytometric analysis in two different processes: 1) after preparation and storage of peripheral blood mononuclear cells (PBMCs) using Ficoll density gradient centrifugation from a human blood sample, 2) followed by isolation and storage of B cells through magnetic separation using a B cell isolation kit and MS column. ELISA assays were performed to observe the cytokine production of interkleukin 10 (IL-10) and transforming growth factor β1 (TGF-β1) by this novel B cell subpopulation. Results Double positive staining of CD5+CD1d+ Bregs represents (19.27 ±1.52) from PBMCs, (33.32 ±2.95) from B cells accordingly (n = 40). Through ELISA assays, it has been found that B cell subpopulation produces IL-10 (0.56 ±0.08) and TGF-β1 (0.90 ±0.12) (n = 40). Conclusions These methods should be able to facilitate progress in research on Bregs through the following steps: 1) the regulatory role may be observed in comparison with particular autoimmune diseases, inflammation, cancer, and immunologic responses to find out whether Breg alteration and/or cytokine production is altered as well in these disorders or conditions. 2) If the alteration of Bregs and cytokine production is significant along with the clinical correlation, a further in vitro study can be initiated with exposure of certain drugs to overcome the alteration of the cytokine production; then, an in vivo study can be initiated.